good for Thank morning, everyone. today. Thanks you, Bill, us joining and
development has results two in XXXX of announced Orexin-X two top disorder, MDD for Xb positive very indications, line insomnia. We and antagonist depressive Phase trials in currently seltorexant, for major been half productive with Minerva. first The
obtained in carried just our we seltorexant. to Phase study was trial. a am study with with pleased biomarker that top This out first in parallel line MDDXXXX I have report Xb results us designated
results on line when MDD call. top later information as seltorexant will further these symptoms depression in So of the a results improvements monotherapy. is provide in patients show I given in
We enrollment roluperidone, good additional trial X include late-stage our progress Phase in trial with seltorexant made have patients a X the been into further Phase with also for trials. of pivotal the completed Xb clinical Phase MIN-XXX. trial the three and recruitment ongoing has which with These
drugs address As time in trial even in you program know, improvement develop to our schizophrenia. in of the needs neuropsychiatric In unmet disorders. patients have to from shown. living medical a first with has drug roluperidone knowledge, the mission Xb been that is this the serious our Phase such lead at Minerva we demonstrated showed remains suffering symptoms the of effect in best specific To specific negative monotherapy patients our
the The both time monotherapy also in data efficacy MDD. class demonstrates duration treatment of recent seltorexant and in for adjunctive first
is Seltorexant this development. knowledge, start stage quarter. X Pharmaceutica with orexin-X have significant only late-state and other are is co-developing selective the seltorexant, a orexin-X the announced today seltorexant we me the antagonist specific let receptor our over So of molecules, we data antagonists. clinical with To with molecule that best Orexin-X in antagonist as NV. last Janssen All
several rhythm of which and extremely linked regulation levels, to sleep-wake These important and system key control include certain sleep in function orexin hyper-arousal, The in is of abnormal and/or metabolic dysregulation, modifications functions, brain functions. lead insomnia. involved to disorders may stress the the like brain
of drugs. not add-on MDD. and/or where as adjunctive XXX antidepressant dosing to This known seltorexant MDDXXXX saw randomized variable effects as was the to with Monotherapy XX this avoid mg of an study. monotherapy of mechanism and and MDDXXXX, moderate-to-severe us conducted the the SNRIs, patients study of SSRIs in chosen evaluate As recent earlier, mg two for seltorexant, and double-blind we XX I than as treatment action study mentioned in placebo-controlled, a multi-sensor, rather alone biomarker treatment study given study to as
The subjective was primary study Response presence XX, and a for Scale, objective disturbance, Severity of of effect Hamilton to sleep this assessment, on placebo analyze the of the treatment ISI the hyper-arousal as Rating a symptoms measured Ruminative Scale seltorexant possible factor of indicator in stratification RRS, patient depression used Insomnia was subjective Depression versus as Index, by as sleep randomization. of HDRSXX,
rumination the that at to significant significant treatment signal disorder, with Scale as Response superior having a statistically least patients announce and mg at superior was for measured p=X.XXXX or dose the and and efficacy a The positive having minutes during showed over pronounced seltorexant more I XX subjective equal versus X am population primarily sleep days sleep to MDD placebo. an endpoint effect XX latency in higher even or ISI analysis to in measured MDD to Ruminative XX has pleased for week-X onset the superior X XX. RRS with nights
with dose statistically disorder was as significant MDD having of While efficacy effect an to week-X, XX. the not improved symptoms the subjective superior show more seltorexant sleep MDD in at significant pronounced a also XX presence and measured patients ISI did mg
and that These seltorexant from their showed as improved patients insomnia. when is study have symptoms positive monotherapy new improvement the that pronounced MDDXXXX also the findings more
the mechanism relationship also of efficacy of clinical action hyper-arousal, support and seltorexant. between the they Importantly,
other and/or to major serotonin-norepinephrine depressive we reuptake inhibitors reuptake to adjunctive XXXX the (SSRIs) inhibitors MDD antidepressant line not seltorexant serotonin XX, May from in On XXXX (SNRIs). results Xb and adequately Phase responding with disorders positive top diagnosed the as trial, of patients announced therapy trial
significant XX at (MADRS) finding score also clinically with Montgomery-Asberg dose to improvement significant the observed statistically and placebo in greater have study, showed Scale profile. the a a was insomnia in In to dose weeks. favorable of this mg tolerability Depression Seltorexant placebo X over compared patients even Rating seltorexant improvement
presentation complete for ACNP Meeting planned are Additional December next Annual the details during this are ongoing in of the year. and analysis of data
a now other release with explored which of press and me study conducted move in Xmg, discussed recent in placebo on was mg, insomnia the study It XX active effects presented a results XX, recently arm during KOL This Let Ambien. June to and was call XXXX. XX our insomnia, from mg an zolpidem, including known controlled elderly seltorexant. of and as patients of ISMXXXX also
in this X mg seltorexant. endpoint, and study doses highly line at significant primary XX after and meaningful XX the Positive to demonstrated clinically Persistent mg Latency improvement Sleep top of Night (NYSE:LPS) results with from treatment statistically
seltorexant of care zolpidem. and endpoints the standard with versus placebo were to addition In primary multiple endpoint, secondary improved
elderly seltorexant the a whose conjunction sleep its in effects elderly suggests in of growing insomnia in Furthermore, potential and benefit patients, including disorders with is of population profile, than of beneficial favorable large in higher patients. prevalence patients the younger tolerability
able symptoms MDD data quarter To the in demonstrated seltorexant patients not is MDD announced mood observed patients these therapies monotherapy. when to depressive improve The treated pronounced first-line are this past responding patients, as insomnia. in with to well with in improvements adequately summarize, the as associated more
adults and associated In superior observed comorbidities zolpidem patients present treatment and with in the these in with observed in after where addition, in elderly. when those improvement improvements and insomnia to neuropsychiatric
profile the major and without therapeutic is Importantly, observed safety as effects placebo. effects tolerability side were seltorexant that comparable of these of to
needs ability seltorexant of three both date, confirms insomnia findings to the medical mood the unique conducted disorders. from to trials in unmet together, address Taken and
Let update trial. in advanced roluperidone, a me on our pivotal now X provide an most Phase program
Europe. enroll XXX We is negative are continuing consistent design Phase The to approximately symptoms. diagnosis trial in This trial and recruit fundamentally trial who patients Xb present of with will our XX Phase this sites approximately with with in patients that clinical the of successful X U.S. of schizophrenia trial. the at
replicate Personal total roluperidone. severity for and into symptoms secondary negative as translates patients statistically demonstrate measured primary is an scores improvement with we two assessing observed functional selecting in scale. negative these in the significant improvements and in which endpoints Furthermore, seeking PSP, treated Social the by scale, that Xb the symptoms which are improvements are endpoints. two constitutes endpoints scale, The are We to reason the to PANSS our in Phase secondary Performance CGI
With has of the I roluperidone. symptoms report Xb Research improvement respect improvement which to in in Schizophrenia ill the observed Phase a effects to study, that our to ways negative publication recently with pleased translates the this that the best is one treated functional the accepted PSP about in scale been the Journal scientific into on patients am show in
the Concerning to U.S. close patient sites includes the to during the selection treatment in key adherence phase. symptoms patient's of is trial. objective Phase ensure on focus main Europe This X study, parameters assessment this in and of monitoring careful and the our of
the of XX-week in We of blind trial expect XXXX. the quarter period data to double the readout from X first Phase treatment
positive clinical standard these a Without types roluperidone currently trial work this interaction. preparatory two from considerable minimal the We of Cytochrome Application, with data going CYPXAX. molecules into interactions forward The of too X Phase moving also the New CYPXDX for details, studies the are pharmacology on study of a a PXXX, NDA DDI sub Drug include many being data we show NDA. part have separately recently preliminary parallel inhibiting with In completed interaction, which a are comprise analyzed and for and drug-drug filing study. focused pending
launch also roluperidone. team of commercial to and positioning the on strategy Our work continue
sites Top U.S. and trial phase, trial are believe our and to last double-blind diagnosis be a have quarter patients XXXX. we treatment period. on patients we XX of study XXX six-week Xb of our associated expected are anxiety. two-week our line study particularly enrolled treatment benefit Moving this continuing post to these a a with from and Patients trial Approximately to with clinical includes the in product, Based are phase, Europe. in that findings results a in in MIN-XXX. clinical followup stage fourth expected in previous MIN-XXX. recruit on may recruited about The with this the patients screening MDD Phase design
treat readouts has half of two seltorexant of We of results for which the really forward this of exciting in our of MIN-XXX. patients clinical clinical demonstrate In the summary, groups therapeutic year second and the the areas potential to roluperidone been with the MDD half that to important for provide molecule will tremendously important XXXX look insomnia. multiple molecules, and first late-stage
Geoff, financials our turn greater describe will now I it over to who in will detail.
